GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its position in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 12.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 538,588 shares of the company’s stock after acquiring an additional 58,465 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in GoodRx were worth $2,504,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Point72 Asset Management L.P. acquired a new position in shares of GoodRx in the third quarter worth $11,295,000. Franklin Resources Inc. acquired a new position in shares of GoodRx in the third quarter worth about $5,675,000. Pier Capital LLC bought a new position in GoodRx during the 3rd quarter valued at $3,259,000. Barclays PLC boosted its holdings in shares of GoodRx by 1,316.1% in the 3rd quarter. Barclays PLC now owns 140,113 shares of the company’s stock valued at $973,000 after buying an additional 130,219 shares during the period. Finally, Fortem Financial Group LLC acquired a new stake in GoodRx in the 3rd quarter valued at approximately $772,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Mizuho assumed coverage on shares of GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective on the stock. Morgan Stanley reduced their target price on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. KeyCorp reduced their price objective on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Citigroup lowered their price target on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research note on Friday, January 10th. Finally, Wells Fargo & Company cut their target price on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, GoodRx presently has a consensus rating of “Moderate Buy” and an average target price of $8.18.

GoodRx Trading Down 0.4 %

Shares of GDRX opened at $4.50 on Friday. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of -150.00, a PEG ratio of 2.46 and a beta of 1.25. The firm’s 50-day moving average price is $4.77 and its 200-day moving average price is $5.31. GoodRx Holdings, Inc. has a 1-year low of $4.09 and a 1-year high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.